Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2007

01-04-2007 | Letter to the Editor

Successful Treatment with Imatinib Combined with Less Intensive Chemotherapy (Vincristine and Dexamethasone) as Induction Therapy in a Very Elderly Patient with Philadelphia Chromosome—Positive Acute Lymphoblastic Leukemia

Authors: Kazuhiro Nishii, Miho Sakakura, Tetsuya Tsukada, Hyou Ryuu, Naoyuki Katayama

Published in: International Journal of Hematology | Issue 3/2007

Login to get access
Metadata
Title
Successful Treatment with Imatinib Combined with Less Intensive Chemotherapy (Vincristine and Dexamethasone) as Induction Therapy in a Very Elderly Patient with Philadelphia Chromosome—Positive Acute Lymphoblastic Leukemia
Authors
Kazuhiro Nishii
Miho Sakakura
Tetsuya Tsukada
Hyou Ryuu
Naoyuki Katayama
Publication date
01-04-2007
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2007
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.06216

Other articles of this Issue 3/2007

International Journal of Hematology 3/2007 Go to the issue

Images in Hematology

Acute Myeloid Leukemia—Cuplike: Characteristic Peroxidase Staining Pattern

Case Report

Reactive Peripheral Blood Plasmacytosis in a Patient with Acute Hepatitis A

OriginalPaper

Peroxisome Proliferator-Activated Receptor γ and Retinoic Acid Receptor Synergistically Up-Regulate the Tumor Suppressor PTEN in Human Promyeloid Leukemia Cells

OriginalPaper

Cyclosporine Therapy for Acquired Aplastic Anemia: Predictive Factors for the Response and Long-term Prognosis

Case Report

Reversible Cardiomyopathy Associated with Multicentric Castleman Disease: Successful Treatment with Tocilizumab, an Anti—Interleukin 6 Receptor Antibody

Letter to the Editor

Trisomy 21 as the Sole Acquired Karyotypic Abnormality in Biphenotypic Acute Leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits